<?xml version="1.0" encoding="UTF-8"?>
<ref id="B170">
 <label>170.</label>
 <mixed-citation publication-type="webpage">
  <person-group person-group-type="author">
   <collab>FDA</collab>
  </person-group>
  <article-title>Recommendations for Investigational COVID-19 Convalescent Plasma</article-title>. (
  <year>2020</year>). Available online at: 
  <ext-link ext-link-type="uri" xlink:href="https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemption-ide-process-cber/recommendations-investigational-covid-19-convalescent-plasma#Patient" xmlns:xlink="http://www.w3.org/1999/xlink">https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemption-ide-process-cber/recommendations-investigational-covid-19-convalescent-plasma#Patient</ext-link> Eligibility (accessed April 9, 2020).
 </mixed-citation>
</ref>
